Sugi Predict

Sugi Predict / Compounds / Hydroquinone

Hydroquinone

Hydroquinone

SCHEMBL578588

CC(O)OC(C)O.OCC1CCC(CO)CC1.Oc1ccc(O)cc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 10/20 0.55
▸ ESR1 P03372 8/20 0.55
▸ CYP3A4 P08684 3/20 0.55
▸ CYP2C9 P11712 2/20 0.55
▸ CYP2D6 P10635 2/20 0.49
▸ GRIN2B Q13224 6/20 0.35
▸ ADRA2A P08913 5/20 0.35
▸ HTR2A P28223 5/20 0.35
▸ ADRA1A P35348 5/20 0.35
▸ GRIN1 Q05586 4/20 0.35
▸ HTR2B P41595 4/20 0.35
▸ SIGMAR1 Q99720 3/20 0.35
▸ GRIN2D O15399 2/20 0.35
▸ HTR1A P08908 2/20 0.35
▸ GRIN2A Q12879 2/20 0.35
▸ GRIN2C Q14957 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ADRB1 P08588 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ ADRA2B P18089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroquinone SCHEMBL408939 0.82 ESR2 (0.75) ESR2ESR1CYP3A4CYP2C9CYP2D6
Hydroquinone SCHEMBL483602 0.79 ESR1 (0.50) ESR2ESR1CYP3A4LMNASLC6A2
Hydroquinone SCHEMBL356143 0.73 ESR2 (0.58) ESR2ESR1CYP3A4CYP2C9CYP2D6
Bisphenol A SCHEMBL28100455 0.72 ESR2 (0.61) ESR2ESR1CYP3A4CYP2C9CYP2D6
Phenol SCHEMBL22542897 0.71 ESR2 (0.61) ESR2ESR1CYP3A4CYP2C9CYP2D6
Phenol SCHEMBL8771544 0.71 ESR2 (0.61) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL23977206 0.71 ESR2 (1.00) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL18244747 0.71 ESR2 (1.00) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL20524202 0.71 ESR2 (1.00) ESR2ESR1CYP3A4CYP2C9CYP2D6
SCHEMBL9177731 0.70 APLNR (0.38) ESR2ESR1CYP3A4CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271391-B1 URETERAL STENTS FOR RELEASE OF UROLOGICALLY BENEFICIAL AGENTS BOSTON SCIENT SCIMED INC (US) 2019-10-30 — — EP disclosed
US-10251741-B2 Ureteral stent with drug-releasing structure BOSTON SCIENTIFIC SCIMED, INC. (US) 2019-04-09 — — US disclosed
EP-2294105-B1 FIBER REINFORCED TPU COMPOSITES LUBRIZOL ADVANCED MAT INC (US) 2018-07-11 — — EP disclosed
US-20160361152-A1 URETERAL STENT WITH DRUG-RELEASING STRUCTURE BOSTON SCIENTIFIC SCIMED, INC. 2016-12-15 — — US disclosed
US-9445884-B2 Ureteral stent with drug-releasing structure BOSTON SCIENTIFIC SCIMED, INC. (US) 2016-09-20 — — US disclosed
US-20140214175-A1 URETERAL STENT WITH DRUG-RELEASING STRUCTURE BOSTON SCIENTIFIC SCIMED, INC. (US) 2014-07-31 — — US disclosed
EP-2486949-A1 Polycarbonate polyurethane venous access devices Navilyst Medical, Inc. (US) 2012-08-15 — — EP disclosed
EP-2342250-B1 TPU COMPOSITIONS FOR MELT COATING PROCESSES LUBRIZOL ADVANCED MAT INC (US) 2012-08-15 — — EP disclosed
EP-2068960-B1 POLYCARBONATE POLYURETHANE VENOUS ACCESS DEVICES NAVILYST MEDICAL INC (US) 2012-02-15 — — EP disclosed
US-8048171-B2 Ureteral stents for release of urologically beneficial agents BOSTON SCIENTIFIC SCIMED, INC. (US) 2011-11-01 — — US disclosed
EP-1874854-A1 NON HALOGEN FLAME RETARDANT THERMOPLASTIC POLYURETHANE Lubrizol Advanced Materials, Inc. (US) 2008-01-09 — — EP disclosed
US-7264858-B2 Multilayered articles having biocompatibility and biostability characteristics LUBRIZOL ADVANCED MATERIALS, INC. (US) 2007-09-04 — — US disclosed
WO-2006121549-A1 NON HALOGEN FLAME RETARDANT THERMOPLASTIC POLYURETHANE LUBRIZOL ADVANCED MATERIALS, INC. (US) 2006-11-16 — — WO disclosed
EP-1235878-B1 EXTRUDABLE POLYURETHANE COMPOSITIONS AND METHODS OF MAKING THEM NOVEON IP HOLDINGS CORP (US) 2005-12-28 — — EP disclosed
US-6777466-B2 WIRE, CABLE JACKET; MOLDING MATERIALS; TENSILE STRENGTH NOVEON IP HOLDINGS CORP. 2004-08-17 — — US disclosed
WO-2004039584-A1 MULTILAYERED ARTICLES HAVING BIOCOMPATIBILITY AND BIOSTABILITY CHARACTERISTICS NOVEON IP HOLDINGS CORP. (US) 2004-05-13 — — WO disclosed
US-20030166749-A1 Flame retardant thermoplastic polyurethane containing melamine cyanurate NOVEON, INC. 2003-09-04 — — US disclosed
US-6458880-B1 POLYESTERURETHANE COPOLYMERS WITH TALC FOR CRYSTALIZATION NOVEON IP HOLDINGS CORP. 2002-10-01 — — US disclosed
US-6297321-B1 Extrudable polyurethane compositions and methods THE B. F. GOODRICH COMPANY 2001-10-02 — — US disclosed
US-5110850-A Wires, cable jackets, blown films B. F. GOODRICH COMPANY (US) 1992-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251741-B2 Ureteral stent with drug-releasing structure UTS2R, KDELR2, KDELR1 ESR2 329/4885ESR1 126/4885CYP3A4 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.